CDT Equity (NASDAQ:CDT) Releases Quarterly Earnings Results

CDT Equity (NASDAQ:CDT) released its quarterly earnings data on Wednesday. The company reported ($8.71) earnings per share (EPS) for the quarter, Zacks reports.

CDT Equity Trading Down 1.0%

NASDAQ CDT opened at $2.93 on Thursday. CDT Equity has a 1-year low of $2.53 and a 1-year high of $3,700.00. The company has a 50 day moving average of $5.33 and a 200-day moving average of $76.35. The firm has a market cap of $1.85 million, a price-to-earnings ratio of -0.00 and a beta of 1.52.

Analyst Upgrades and Downgrades

A number of equities analysts have recently commented on the stock. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of CDT Equity in a report on Wednesday, June 24th. Wall Street Zen upgraded shares of CDT Equity from a “strong sell” rating to a “sell” rating in a research note on Saturday, August 1st. One investment analyst has rated the stock with a Sell rating, According to data from MarketBeat, the company has a consensus rating of “Sell”.

About CDT Equity

Conduit Pharmaceuticals Inc, a clinical-stage specialty biopharmaceutical company, develops pharmaceutical products that provides unmet medical needs in the areas of autoimmune diseases and idiopathic male infertility. Its pipeline includes AZD1656, which has completed Phase I trials for the treatment of type 2 diabetes, renal transplant, Hashimoto's thyroiditis and Grave's disease, uveitis, and preterm labor; and AZD5904, which has completed Phase I clinical trials for the treatment of idiopathic male infertility.